Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

Rosalinde E R Slot; Sander C J Verfaillie; Jozefien M Overbeek; Tessa Timmers; Linda M P Wesselman; Charlotte E Teunissen; Annemiek Dols; Femke H Bouwman; Niels D Prins; Frederik Barkhof; Adriaan A Lammertsma; Bart N M Van Berckel; Philip Scheltens; Sietske A M Sikkes; Wiesje M Van der Flier

doi:10.1186/s13195-018-0390-y

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

Rosalinde E R Slot, Sander C J Verfaillie, Jozefien M Overbeek, Tessa Timmers, Linda M P Wesselman, Charlotte E Teunissen, Annemiek Dols, Femke H Bouwman, Niels D Prins, Frederik Barkhof, Adriaan A Lammertsma, Bart N M Van Berckel, Philip Scheltens, Sietske A M Sikkes, Wiesje M Van der Flier

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.

METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.

RESULTS: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer's disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7-38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6-15.0)) were associated with preclinical AD.

CONCLUSIONS: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.

Original language	English
Article number	76
Pages (from-to)	76
Journal	Alzheimer's Research & Therapy
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s13195-018-0390-y
Publication status	Published - 7 Aug 2018
Externally published	Yes

Keywords

Aged
Amyloid beta-Peptides/cerebrospinal fluid
Amyloid/metabolism
Apolipoprotein E4/genetics
Cognitive Dysfunction/complications
Cohort Studies
Cross-Sectional Studies
Disease Progression
Female
Humans
Magnetic Resonance Imaging
Male
Mental Disorders/etiology
Mental Status and Dementia Tests
Middle Aged
Neuropsychological Tests
Peptide Fragments/cerebrospinal fluid
Positron-Emission Tomography
Research Design
Surveys and Questionnaires
tau Proteins/cerebrospinal fluid

Access to Document

10.1186/s13195-018-0390-y

Cite this

Slot, R. E. R., Verfaillie, S. C. J., Overbeek, J. M., Timmers, T., Wesselman, L. M. P., Teunissen, C. E., Dols, A., Bouwman, F. H., Prins, N. D., Barkhof, F., Lammertsma, A. A., Van Berckel, B. N. M., Scheltens, P., Sikkes, S. A. M., & Van der Flier, W. M. (2018). Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research & Therapy, 10(1), 76. Article 76. https://doi.org/10.1186/s13195-018-0390-y

@article{d6c732d74b2c4762b86ae0d1e349eae7,

title = "Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results",

abstract = "BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.RESULTS: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer's disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7-38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6-15.0)) were associated with preclinical AD.CONCLUSIONS: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.",

keywords = "Aged, Amyloid beta-Peptides/cerebrospinal fluid, Amyloid/metabolism, Apolipoprotein E4/genetics, Cognitive Dysfunction/complications, Cohort Studies, Cross-Sectional Studies, Disease Progression, Female, Humans, Magnetic Resonance Imaging, Male, Mental Disorders/etiology, Mental Status and Dementia Tests, Middle Aged, Neuropsychological Tests, Peptide Fragments/cerebrospinal fluid, Positron-Emission Tomography, Research Design, Surveys and Questionnaires, tau Proteins/cerebrospinal fluid",

author = "Slot, {Rosalinde E R} and Verfaillie, {Sander C J} and Overbeek, {Jozefien M} and Tessa Timmers and Wesselman, {Linda M P} and Teunissen, {Charlotte E} and Annemiek Dols and Bouwman, {Femke H} and Prins, {Niels D} and Frederik Barkhof and Lammertsma, {Adriaan A} and {Van Berckel}, {Bart N M} and Philip Scheltens and Sikkes, {Sietske A M} and {Van der Flier}, {Wiesje M}",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = aug,

day = "7",

doi = "10.1186/s13195-018-0390-y",

language = "English",

volume = "10",

pages = "76",

journal = "Alzheimer's Research & Therapy",

issn = "1758-9193",

publisher = "BioMed Central",

number = "1",

}

Slot, RER, Verfaillie, SCJ, Overbeek, JM, Timmers, T, Wesselman, LMP, Teunissen, CE, Dols, A, Bouwman, FH, Prins, ND, Barkhof, F, Lammertsma, AA, Van Berckel, BNM, Scheltens, P, Sikkes, SAM & Van der Flier, WM 2018, 'Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results', Alzheimer's Research & Therapy, vol. 10, no. 1, 76, pp. 76. https://doi.org/10.1186/s13195-018-0390-y

TY - JOUR

T1 - Subjective Cognitive Impairment Cohort (SCIENCe)

T2 - study design and first results

AU - Slot, Rosalinde E R

AU - Verfaillie, Sander C J

AU - Overbeek, Jozefien M

AU - Timmers, Tessa

AU - Wesselman, Linda M P

AU - Teunissen, Charlotte E

AU - Dols, Annemiek

AU - Bouwman, Femke H

AU - Prins, Niels D

AU - Barkhof, Frederik

AU - Lammertsma, Adriaan A

AU - Van Berckel, Bart N M

AU - Scheltens, Philip

AU - Sikkes, Sietske A M

AU - Van der Flier, Wiesje M

PY - 2018/8/7

Y1 - 2018/8/7

N2 - BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.RESULTS: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer's disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7-38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6-15.0)) were associated with preclinical AD.CONCLUSIONS: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.

AB - BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.RESULTS: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer's disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7-38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6-15.0)) were associated with preclinical AD.CONCLUSIONS: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.

KW - Aged

KW - Amyloid beta-Peptides/cerebrospinal fluid

KW - Amyloid/metabolism

KW - Apolipoprotein E4/genetics

KW - Cognitive Dysfunction/complications

KW - Cohort Studies

KW - Cross-Sectional Studies

KW - Disease Progression

KW - Female

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Mental Disorders/etiology

KW - Mental Status and Dementia Tests

KW - Middle Aged

KW - Neuropsychological Tests

KW - Peptide Fragments/cerebrospinal fluid

KW - Positron-Emission Tomography

KW - Research Design

KW - Surveys and Questionnaires

KW - tau Proteins/cerebrospinal fluid

U2 - 10.1186/s13195-018-0390-y

DO - 10.1186/s13195-018-0390-y

M3 - Article

C2 - 30081935

SN - 1758-9193

VL - 10

SP - 76

JO - Alzheimer's Research & Therapy

JF - Alzheimer's Research & Therapy

IS - 1

M1 - 76

ER -

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

Abstract

Keywords

Access to Document

Fingerprint

Cite this